Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 35  |  Issue : 4  |  Page : 1772-1778

Serum beta-2 microglobulin in patients with chronic hepatitis C virus with or without hepatocellular carcinoma


1 Department of Tropical Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Hepatogastroentrology and Infectious Diseases, Shebin-Elkom Teaching Hospital, Menoufia, Egypt
3 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Randa M Seddik
Shebin-Elkom, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_278_22

Rights and Permissions

Objectives To investigate serum beta-2 microglobulin (B2M) as a noninvasive marker for disease progression in chronic hepatitis C virus (HCV)-infected patients and to study its role as a tumor marker in diagnosis of hepatocellular carcinoma (HCC). Background HCV is a hepatotropic RNA virus that causes progressive liver damage, which might result in liver cirrhosis and HCC. Patients and methods From January 2020 to January 2022, this prospective study was carried on 136 participants who were classified into four groups: group I, 22 patients with noncirrhotic chronic hepatitis C; group II, 70 HCV-related cirrhotic patients; group III, 25 patients with HCC on top of HCV; and group IV, 19 healthy controls. Serum B2M was quantitatively measured in all of the studied groups. Results B2M was significantly higher in diseased groups than the control group, and it was significantly higher in cirrhosis and HCC groups than the chronic HCV group (P<0.001). The B2M cutoff value for HCC with cirrhosis group was 7.35, with sensitivity of 72.4% and specificity 60.1%, whereas the cutoff value for cirrhosis with chronic HCV group was 6.25. The sensitivity for HCC diagnosis increased upon combining B2M and alpha-fetoprotein, to be 96.4%, and specificity was 80%. Conclusion Serum B2M level was elevated in HCV-related chronic liver diseases and may be used as a marker for HCV disease progression toward cirrhosis and HCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed607    
    Printed24    
    Emailed0    
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal